Fennec Pharmaceuticals weekly recap highlights PEDMARK momentum

Fennec Pharmaceuticals reported revenue growth and positive EBITDA from commercial execution. The company attributes sales to PEDMARK, its sole FDA-approved drug to prevent cisplatin hearing loss, and cites IP protection, partners, and planned expansion into Europe, Japan and adult markets.